{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:58:20Z","timestamp":1789988300795,"version":"4.0.1"},"reference-count":49,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The mammalian target of rapamycin (mTOR) plays crucial roles in proliferative and antiapoptotic signaling in lymphoid malignancies. Rapamycin analogs, which are allosteric mTOR complex 1 (mTORC1) inhibitors, are active in mantle cell lymphoma and other lymphoid neoplasms, but responses are usually partial and short-lived. In the present study we compared the effects of rapamycin with the dual mTORC1\/mTORC2 inhibitor OSI-027 in cell lines and clinical samples representing divers lymphoid malignancies. In contrast to rapamycin, OSI-027 markedly diminished proliferation and induced apoptosis in a variety of lymphoid cell lines and clinical samples, including specimens of B-cell acute lymphocytic leukemia (ALL), mantle cell lymphoma, marginal zone lymphoma and Sezary syndrome. Additional analysis demonstrated that OSI-027\u2013induced apoptosis depended on transcriptional activation of the PUMA and BIM genes. Overexpression of Bcl-2, which neutralizes Puma and Bim, or loss of procaspase 9 diminished OSI-027\u2013induced apoptosis in vitro. Moreover, OSI-027 inhibited phosphorylation of mTORC1 and mTORC2 substrates, up-regulated Puma, and induced regressions in Jeko xenografts. Collectively, these results not only identify a pathway that is critical for the cytotoxicity of dual mTORC1\/mTORC2 inhibitors, but also suggest that simultaneously targeting mTORC1 and mTORC2 might be an effective anti-lymphoma strategy in vivo.<\/jats:p>","DOI":"10.1182\/blood-2011-04-346601","type":"journal-article","created":{"date-parts":[[2011,11,12]],"date-time":"2011-11-12T08:48:48Z","timestamp":1321087728000},"page":"476-487","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":93,"title":["Dual mTORC1\/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies"],"prefix":"10.1182","volume":"119","author":[{"given":"Mamta","family":"Gupta","sequence":"first","affiliation":[{"name":"Departments of Medicine, Oncology and Pharmacology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea E. Wahner","family":"Hendrickson","sequence":"additional","affiliation":[{"name":"Departments of Medicine, Oncology and Pharmacology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Seok","family":"Yun","sequence":"additional","affiliation":[{"name":"Departments of Medicine, Oncology and Pharmacology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing Jing","family":"Han","sequence":"additional","affiliation":[{"name":"Departments of Medicine, Oncology and Pharmacology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula A.","family":"Schneider","sequence":"additional","affiliation":[{"name":"Departments of Medicine, Oncology and Pharmacology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian D.","family":"Koh","sequence":"additional","affiliation":[{"name":"Departments of Medicine, Oncology and Pharmacology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary J.","family":"Stenson","sequence":"additional","affiliation":[{"name":"Departments of Medicine, Oncology and Pharmacology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda E.","family":"Wellik","sequence":"additional","affiliation":[{"name":"Departments of Medicine, Oncology and Pharmacology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer C.","family":"Shing","sequence":"additional","affiliation":[{"name":"Departments of Medicine, Oncology and Pharmacology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Peterson","sequence":"additional","affiliation":[{"name":"Departments of Medicine, Oncology and Pharmacology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen S.","family":"Flatten","sequence":"additional","affiliation":[{"name":"Departments of Medicine, Oncology and Pharmacology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan D.","family":"Hess","sequence":"additional","affiliation":[{"name":"Departments of Medicine, Oncology and Pharmacology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Douglas","family":"Smith","sequence":"additional","affiliation":[{"name":"Departments of Medicine, Oncology and Pharmacology, Mayo Clinic, Rochester, MN;"},{"name":"Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith E.","family":"Karp","sequence":"additional","affiliation":[{"name":"Departments of Medicine, Oncology and Pharmacology, Mayo Clinic, Rochester, MN;"},{"name":"Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Barr","sequence":"additional","affiliation":[{"name":"Departments of Medicine, Oncology and Pharmacology, Mayo Clinic, Rochester, MN;"},{"name":"OSI Pharmaceuticals, Farmingdale, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[{"name":"Departments of Medicine, Oncology and Pharmacology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott H.","family":"Kaufmann","sequence":"additional","affiliation":[{"name":"Departments of Medicine, Oncology and Pharmacology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2019111814370339000_B1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010.","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"2019111814370339000_B2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/asheducation-2010.1.265","article-title":"Signal transduction inhibitor therapy for lymphoma.","volume":"2010","author":"Witzig","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"2019111814370339000_B3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc1362","article-title":"The TOR pathway: a target for cancer therapy.","volume":"4","author":"Bjornsti","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"2019111814370339000_B4","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.bbapap.2009.12.001","article-title":"Dissecting the role of mTOR: lessons from mTOR inhibitors.","volume":"1804","author":"Dowling","year":"2010","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"2019111814370339000_B5","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.molcel.2010.09.026","article-title":"Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress.","volume":"40","author":"Sengupta","year":"2010","journal-title":"Mol Cell"},{"issue":"1","key":"2019111814370339000_B6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer.","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"issue":"5","key":"2019111814370339000_B7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrm2672","article-title":"Molecular mechanisms of mTOR-mediated translational control.","volume":"10","author":"Ma","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"48","key":"2019111814370339000_B8","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1038\/sj.onc.1209886","article-title":"mTOR and cancer therapy.","volume":"25","author":"Easton","year":"2006","journal-title":"Oncogene"},{"issue":"10","key":"2019111814370339000_B9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.molmed.2007.08.001","article-title":"Targeting the mTOR signaling network in cancer.","volume":"13","author":"Chiang","year":"2007","journal-title":"Trends Mol Med"},{"issue":"23","key":"2019111814370339000_B10","first-page":"8451","article-title":"Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells.","volume":"63","author":"Edinger","year":"2003","journal-title":"Cancer Res"},{"issue":"45","key":"2019111814370339000_B11","doi-asserted-by":"crossref","first-page":"17414","DOI":"10.1073\/pnas.0809136105","article-title":"Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation.","volume":"105","author":"Choo","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"2019111814370339000_B12","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nrc1974","article-title":"mTOR and cancer: insights into a complex relationship.","volume":"6","author":"Sabatini","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"6035","key":"2019111814370339000_B13","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1126\/science.1199498","article-title":"The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling.","volume":"332","author":"Hsu","year":"2011","journal-title":"Science"},{"issue":"8","key":"2019111814370339000_B14","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1182\/blood-2006-06-030833","article-title":"Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.","volume":"109","author":"Zeng","year":"2007","journal-title":"Blood"},{"issue":"11","key":"2019111814370339000_B15","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1158\/1078-0432.CCR-06-2798","article-title":"The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy.","volume":"13","author":"Abraham","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2019111814370339000_B16","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1158\/0008-5472.CAN-09-2340","article-title":"Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.","volume":"70","author":"Yu","year":"2010","journal-title":"Cancer Res"},{"issue":"1","key":"2019111814370339000_B17","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/0008-5472.CAN-09-1751","article-title":"AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.","volume":"70","author":"Chresta","year":"2010","journal-title":"Cancer Res"},{"issue":"2","key":"2019111814370339000_B18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nm.2091","article-title":"Effective and selective targeting of leukemia cells using a TORC1\/2 kinase inhibitor.","volume":"16","author":"Janes","year":"2010","journal-title":"Nat Med"},{"issue":"5","key":"2019111814370339000_B19","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1158\/0008-5472.CAN-10-3126","article-title":"Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1\/mTORC2 inhibitors.","volume":"71","author":"Falcon","year":"2011","journal-title":"Cancer Res"},{"issue":"8","key":"2019111814370339000_B20","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1158\/1535-7163.MCT-10-1099","article-title":"Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin.","volume":"10","author":"Bhagwat","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"28","key":"2019111814370339000_B21","doi-asserted-by":"crossref","first-page":"12469","DOI":"10.1073\/pnas.1005114107","article-title":"Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells.","volume":"107","author":"Carayol","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2019111814370339000_B22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1023\/A:1024116916932","article-title":"Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties.","volume":"8","author":"Caserta","year":"2003","journal-title":"Apoptosis"},{"issue":"47","key":"2019111814370339000_B23","doi-asserted-by":"crossref","first-page":"47326","DOI":"10.1074\/jbc.M304793200","article-title":"Central role of FADD in apoptosis induction by the mitogen activated activated protein kinase kinase inhibitor CI1040 (PD184352) in acute lymphocytic leukemia cell lines in vitro.","volume":"278","author":"Meng","year":"2003","journal-title":"J Biol Chem"},{"issue":"20","key":"2019111814370339000_B24","doi-asserted-by":"crossref","first-page":"17682","DOI":"10.1074\/jbc.M110.189092","article-title":"Noxa\/Bcl-2 interactions contribute to bortezomib resistance in human lymphoid cells.","volume":"286","author":"Smith","year":"2011","journal-title":"J Biol Chem"},{"issue":"1","key":"2019111814370339000_B25","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/blood-2004-09-3523","article-title":"Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.","volume":"106","author":"Mesa","year":"2005","journal-title":"Blood"},{"issue":"14","key":"2019111814370339000_B26","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1182\/blood-2009-05-220889","article-title":"Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2.","volume":"114","author":"Gupta","year":"2009","journal-title":"Blood"},{"issue":"27","key":"2019111814370339000_B27","doi-asserted-by":"crossref","first-page":"18311","DOI":"10.1074\/jbc.M109.004770","article-title":"Context-dependent Bcl-2\/Bak Interactions Regulate Lymphoid Cell Apoptosis.","volume":"284","author":"Dai","year":"2009","journal-title":"J Biol Chem"},{"issue":"6","key":"2019111814370339000_B28","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood.V89.6.2098","article-title":"Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells.","volume":"89","author":"Kaufmann","year":"1997","journal-title":"Blood"},{"issue":"2","key":"2019111814370339000_B29","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1006\/abio.2001.5313","article-title":"Reutilization of immunoblots after chemiluminescent detection.","volume":"296","author":"Kaufmann","year":"2001","journal-title":"Anal Biochem"},{"issue":"30","key":"2019111814370339000_B30","doi-asserted-by":"crossref","first-page":"20227","DOI":"10.1074\/jbc.M109.027201","article-title":"Runx1 is a co-activator with FOXO3 to mediate transforming growth factor beta (TGFbeta)-induced Bim transcription in hepatic cells.","volume":"284","author":"Wildey","year":"2009","journal-title":"J Biol Chem"},{"issue":"4","key":"2019111814370339000_B31","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.cell.2005.09.029","article-title":"Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing puma.","volume":"123","author":"Wu","year":"2005","journal-title":"Cell"},{"issue":"2","key":"2019111814370339000_B32","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ccr.2006.07.003","article-title":"Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin.","volume":"10","author":"Phung","year":"2006","journal-title":"Cancer Cell"},{"issue":"21","key":"2019111814370339000_B33","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1182\/blood-2008-09-179762","article-title":"A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation.","volume":"113","author":"Gupta","year":"2009","journal-title":"Blood"},{"issue":"5","key":"2019111814370339000_B34","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/leu.2011.20","article-title":"Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia.","volume":"25","author":"Evangelisti","year":"2011","journal-title":"Leukemia"},{"issue":"1","key":"2019111814370339000_B35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.molcel.2005.03.008","article-title":"PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth.","volume":"18","author":"Gao","year":"2005","journal-title":"Mol Cell"},{"issue":"6","key":"2019111814370339000_B36","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.molcel.2007.02.017","article-title":"PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms.","volume":"25","author":"Brognard","year":"2007","journal-title":"Mol Cell"},{"issue":"4","key":"2019111814370339000_B37","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1158\/1078-0432.CCR-10-2634","article-title":"Principles and current strategies for targeting autophagy for cancer treatment.","volume":"17","author":"Amaravadi","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2019111814370339000_B38","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1101\/gad.13.22.2905","article-title":"Cellular survival: a play in three Akts.","volume":"13","author":"Datta","year":"1999","journal-title":"Genes Dev"},{"issue":"3","key":"2019111814370339000_B39","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1042\/BJ20081056","article-title":"The life of a cell: apoptosis regulation by the PI3K\/PKB pathway.","volume":"415","author":"Duronio","year":"2008","journal-title":"Biochem J"},{"issue":"3","key":"2019111814370339000_B40","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrm2312","article-title":"Apoptosis: controlled demolition at the cellular level.","volume":"9","author":"Taylor","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"2019111814370339000_B41","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrm2308","article-title":"The BCL-2 protein family: opposing activities that mediate cell death.","volume":"9","author":"Youle","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"2019111814370339000_B42","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.molcel.2010.01.025","article-title":"The BCL-2 family reunion.","volume":"37","author":"Chipuk","year":"2010","journal-title":"Mol Cell"},{"issue":"6009","key":"2019111814370339000_B43","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1126\/science.1190217","article-title":"BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program.","volume":"330","author":"Ren","year":"2010","journal-title":"Science"},{"issue":"15","key":"2019111814370339000_B44","doi-asserted-by":"crossref","first-page":"6232","DOI":"10.1158\/0008-5472.CAN-09-0299","article-title":"Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.","volume":"69","author":"Yu","year":"2009","journal-title":"Cancer Res"},{"issue":"4","key":"2019111814370339000_B45","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ccr.2006.09.006","article-title":"Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance.","volume":"10","author":"Wei","year":"2006","journal-title":"Cancer Cell"},{"issue":"4","key":"2019111814370339000_B46","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/cdd.2010.191","article-title":"The Beclin 1 network regulates autophagy and apoptosis.","volume":"18","author":"Kang","year":"2011","journal-title":"Cell Death Differ"},{"issue":"5","key":"2019111814370339000_B47","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1074\/jbc.M107218200","article-title":"Phorbol-12-myristate 13-acetate inhibits death receptor-mediated apoptosis in Jurkat cells by disrupting FADD recruitment.","volume":"277","author":"Meng","year":"2002","journal-title":"J Biol Chem"},{"issue":"6495","key":"2019111814370339000_B48","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/371346a0","article-title":"Cleavage of poly(ADP-ribose)polymerase by a proteinase with properties like ICE.","volume":"371","author":"Lazebnik","year":"1994","journal-title":"Nature"},{"issue":"13","key":"2019111814370339000_B49","first-page":"3487","article-title":"Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan.","volume":"54","author":"Friedman","year":"1994","journal-title":"Cancer Res"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/2\/476\/1497713\/zh800212000476.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/2\/476\/1497713\/zh800212000476.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T19:37:38Z","timestamp":1574105858000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/2\/476\/105516\/Dual-mTORC1mTORC2-inhibition-diminishes-Akt"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,12]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,1,12]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-04-346601","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,12]]}}}